Specimen Validity Testing Market Share, Size, Trends, Industry Analysis Report, By Type (Laboratory Testing, Rapid/POC Testing); By Product & Service; By Drug Type; By Indication; By End User; By Region; Segment Forecast, 2024 - 2032

Specimen Validity Testing Market Share, Size, Trends, Industry Analysis Report, By Type (Laboratory Testing, Rapid/POC Testing); By Product & Service; By Drug Type; By Indication; By End User; By Region; Segment Forecast, 2024 - 2032

The global specimen validity testing market size is expected to reach USD 2.52 billion by 2032, according to a new study by Polaris Market Research. The report “Specimen Validity Testing Market Share, Size, Trends, Industry Analysis Report, By Type (Laboratory Testing, Rapid/POC Testing); By Product & Service; By Drug Type; By Indication; By End User; By Region; Segment Forecast, 2023 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The rising need for abuse testing at the global level highly drives the growth of the specimen validity testing market. The potential to identify the individual's drug intake and other food intake with specimen validity testing is facilitating its adoption in legal and forensic science activities. The significant rise in sample tampering and growing concerns about the security and safety of urine samples encouraged legal officers to check the integrity of the sample with specimen validity testing tools.

The capability to determine adulteration, dilution, and tampering is the primary factor contributing to its adoption in the workplace, drug testing, criminal justice system, and other sectors of the global marketplace. As incorrect drug test results can cause harm to several people, there is increasing demand for medical tests to determine the reliability of the drug tests.

Specimen validity testing is widely conducted on individuals in sensitive places in the regulated sector, such as airplanes, rail, motor carriers, and other transits. The government's initiatives to adopt effective drug testing tools to safeguard the population are likely to propel market growth. For instance, in May 2023, the Department of Transportation (DOT) introduced oral drug testing as an alternative to urine testing.

Stringent regulations globally to improve safety at the workplace and in transportation are anticipated to create diverse opportunities for specimen validity testing. Furthermore, ongoing research studies are exploring potential technologies to determine synthetic urine and create new specimen validity testing. For instance, a 2023 study published in WILEY magazine conducted a review on sample manipulation testing.

Specimen Validity Testing Market Report Highlights

• The laboratory testing segment is anticipated to witness the highest growth due to the growing number of laboratories providing urine testing services.
• The products segment accounted for the largest market share owing to the continuous need for urine testing activities.
• The antiviral drugs segment is projected to experience a larger revenue share due to the prevalence of viral infections.
• Asia Pacific is projected to register the fastest growth during the forecast period due to the rising number of drug screening tests in the region.
• The global players include Abbott, Alfa Scientific Designs, Healgen Scientific, LabCorp, Nona Scientific Laboratory, Omega Laboratories, & Premier Biotech.

Polaris Market Research has segmented the specimen validity testing market report based on product & service, type, drug type, indication, end user and region:

Specimen Validity Testing, Type Outlook (Revenue - USD Billion, 2019 - 2032)

• Laboratory Testing
• Rapid/POC Testing

Specimen Validity Testing, Product & Service Outlook (Revenue - USD Billion, 2019 - 2032)

• Products

- Assay Kits

- Reagents and Calibrators

- Disposables

• Services

Specimen Validity Testing, Drug Type Outlook (Revenue - USD Billion, 2019 - 2032)

• Antibacterial Drugs
• Antifungal Drugs
• Antiviral Drugs
• Others

Specimen Validity Testing, Indication Outlook (Revenue - USD Billion, 2019 - 2032)

• Bloodstream Infections
• Urinary Tract Infections
• Surgical Site Infections
• Pneumonia
• Others

Specimen Validity Testing, End User Outlook (Revenue - USD Billion, 2019 - 2032)

• Drug Screening Laboratories
• Pain Management Centers
• Drug Rehabilitation Centre
• Workplace
• Others

Specimen Validity Testing, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

• North America

- U.S.

- Canada

• Europe

- Germany

- UK

- France

- Italy

- Spain

- Russia

- Netherlands

- Rest of Europe

• Asia Pacific

- China

- India

- Japan

- South Korea

- Indonesia

- Malaysia

- Australia

- Rest of Asia Pacific

• Latin America

- Argentina

- Brazil

- Mexico

- Rest Latin America

• Middle East & Africa

- UAE

- Saudi Arabia

- Israel

- South Africa

- Rest of Middle East & Africa